Profile data is unavailable for this security.
About the company
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
- Revenue in CHF (TTM)337.30m
- Net income in CHF-31.60m
- Incorporated2021
- Employees1.37k
- LocationPolyPeptide Group AGNeuhofstrasse 24BAAR 6340SwitzerlandCHE
- Phone+41 435020580
- Websitehttps://www.polypeptide.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heilongjiang ZBD Pharmaceutical Co Ltd | 180.69m | -37.66m | 833.15m | 2.35k | -- | 1.01 | -- | 4.61 | -0.3545 | -0.3545 | 1.70 | 7.75 | 0.1303 | 0.6358 | 0.4977 | 679,399.90 | -2.74 | 3.29 | -3.80 | 4.46 | 44.16 | 37.24 | -21.03 | 10.59 | 1.33 | -1.45 | 0.3114 | 24.43 | -13.90 | -3.87 | -7.30 | 1.41 | 1.13 | -7.12 |
| Day One Biopharmaceuticals Inc | 123.26m | -83.63m | 834.73m | 178.00 | -- | 2.42 | -- | 6.77 | -1.04 | -1.04 | 1.53 | 4.28 | 0.2901 | 3.57 | 7.79 | 888,662.90 | -19.68 | -32.37 | -22.44 | -35.43 | 89.12 | -- | -67.85 | -209.67 | 7.91 | -- | 0.00 | -- | 20.60 | -- | -12.38 | -- | 110.70 | -- |
| Frontier Biotechnologies Inc | 15.99m | -18.99m | 835.48m | 302.00 | -- | 7.52 | -- | 52.26 | -0.4478 | -0.4478 | 0.377 | 2.62 | 0.0775 | 1.78 | 2.74 | 467,559.50 | -9.21 | -12.65 | -12.08 | -14.50 | 32.51 | 18.59 | -118.79 | -333.96 | 2.58 | -- | 0.3472 | -- | 13.32 | 44.07 | 38.78 | -- | -35.01 | -- |
| Polypeptide Group AG | 337.30m | -31.60m | 845.11m | 1.37k | -- | 2.79 | -- | 2.51 | -0.949 | -0.949 | 10.08 | 9.13 | 0.5153 | 2.06 | 6.35 | 261,272.20 | -4.83 | 0.555 | -6.57 | 0.7099 | 11.63 | 19.25 | -9.37 | 1.05 | 0.8234 | -0.1909 | 0.2517 | 62.37 | 4.28 | 10.70 | 61.97 | -- | 34.57 | -- |
| Wuhan Keqian Biology Co Ltd | 114.84m | 52.03m | 861.30m | 924.00 | 16.66 | 1.82 | -- | 7.50 | 0.9796 | 0.9796 | 2.16 | 8.95 | 0.2209 | 2.86 | 3.23 | 1,097,706.00 | 9.97 | 11.71 | 11.17 | 13.56 | 65.26 | 73.57 | 45.16 | 44.51 | 5.02 | -- | 0.0017 | 32.23 | -11.48 | 13.17 | -3.43 | 9.52 | -4.93 | -- |
| Cisen Pharmaceutical Co Ltd | 403.42m | 55.80m | 866.32m | 3.30k | 15.58 | 1.24 | -- | 2.15 | 1.08 | 1.08 | 7.84 | 13.59 | 0.472 | 2.10 | 5.34 | 1,079,074.00 | 6.58 | 6.51 | 8.12 | 8.07 | 53.70 | 55.92 | 13.94 | 10.84 | 3.48 | -- | 0.0069 | 37.16 | -10.77 | -0.6464 | -2.38 | -0.2215 | -0.3051 | 10.42 |
| Sanofi Consumer Healthcare India Ltd | 74.74m | 20.43m | 867.38m | 583.00 | 42.46 | 26.55 | 40.49 | 11.61 | 104.25 | 104.25 | 381.40 | 166.73 | 1.80 | 4.48 | 40.57 | -- | 49.09 | -- | 66.76 | -- | 73.80 | -- | 27.33 | -- | 3.37 | 148.65 | 0.0607 | -- | 21.24 | -- | 32.65 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to PolyPeptide Group AG's reporting currency: Swiss Franc CHF
19.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Premier Fund Managers Ltd.as of 31 Dec 2024 | 1.71m | 5.17% |
| Newtyn Management LLCas of 04 Jul 2024 | 993.57k | 3.00% |
| PRIMECAP Management Co.as of 31 Oct 2024 | 990.44k | 2.99% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 498.50k | 1.51% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Jan 2026 | 480.03k | 1.45% |
| UBS Asset Management Switzerland AGas of 03 Feb 2026 | 477.08k | 1.44% |
| Vontobel Asset Management AGas of 31 Jan 2026 | 393.67k | 1.19% |
| BlackRock Investment Management (UK) Ltd.as of 31 Jan 2026 | 327.74k | 0.99% |
| HBM Partners AG (Investment Management)as of 31 Dec 2025 | 308.00k | 0.93% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 31 Jan 2025 | 217.50k | 0.66% |
More ▼
Data from 28 Nov 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
